
|Articles|October 23, 2012
FDA approves perampanel as adjunctive treatment for partial-onset seizures in patients with epilepsy aged 12 years and older
FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Q&A: Why Community Pharmacies are Displeased with the MDPNP | NCPA 2025
2
COVID-19 Vaccination Benefits Patients With Systemic Lupus Erythematosus
3
General Awareness of PBM Practices Driving Optimism for Independent Pharmacies | NCPA 2025
4
FDA Releases Biosimilar Guidance Pushing to Streamline Development
5




















































































































































